## **Special Issue**

# Advances in Esophageal Cancer Treatment

## Message from the Guest Editors

We are launching a Special Issue of *Cancers* entitled "Advances in Esophagogastric Cancer". Our aim is to present an overview of the current debates in the treatment of Advances in esophagogastric cancer and to investigate the future impact of the newly introduced advances in the field. This Special Issue will focus on the development of the robot-assisted approach and diagnostic tools with the implementation of deep learning, radiomics and pathomics. At the same time, our goal is to enlighten the role of immunotherapy in the curative and palliative treatment of esophageal cancer, the current and future investigations on the genetics of the disease, organ-sparing treatments, the therapeutic approach to oligometastatic disease, the comparison between the proton versus photon beam radiation, and the advantages and limitations of follow-up protocols after curative treatment. The indicators for quality of care in esophageal malignancy, along with the evaluation of the existing databases from high-volume centers worldwide, stand among this Special Issue's focuses. You are highly welcome to submit an original article/review/meta-analysis to this Special Issue.

#### **Guest Editors**

Dr. B.P.L. (Bas) Wijnhoven

Dr. Richard Skipworth

Dr. Pieter Van der Sluis

Dr. Tania Triantafyllou

## Deadline for manuscript submissions

closed (30 November 2025)



## Cancers

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



mdpi.com/si/194114

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers





## **Cancers**

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



## **About the Journal**

## Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

#### **Editor-in-Chief**

Prof. Dr. Samuel C. Mok.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

### **Author Benefits**

## **Open Access:**

free for readers, with article processing charges (APC) paid by authors or their institutions.

## **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

